Novavax

NOVAVAX INC

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Biotech

Regulations

Health Care

General

NVAX

La decisione del CDC sui vaccini COVID-19 ha generato un acceso dibattito tra gli esperti di sanità pubblica.

Vaccini COVID-19: basta per bambini sani e donne in gravidanza

Large Cap

News

CVAC

MRNA

Quali sono le aziende pronte a rispondere all&#39;emergenza e come potrebbe impattare sul mercato azionario? Ecco i dettagli.

Allarme influenza aviaria: nuovo caso in USA. Ecco 4 azioni da tenere d&#39;occhio

Equities

Markets

IDNA

Un terremoto nella sanità pubblica globale getta ombre sul futuro della lotta alle pandemie. Investitori in allerta e borse in fermento.

Scaricata l&#39;OMS in piena pandemia? Caos sanitario e mercati nel panico

Novavax Inc

Offerings

Press Releases

Novavax Announces Convertible Debt Refinancing

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

Novavax to Participate in the Cantor Global Healthcare Conference

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

Novavax Announces Progress on Sanofi Agreement

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Earnings

Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

AnaptysBio

Ardelyx

BridgeBio Oncology Therapeutics, Inc. - Common Stock

BridgeBio Oncology

CureVac

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Immunome

Immatics

Inhibrx Biosciences

MiMedx Group

NuCana

Nurix Therapeutics

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Precigen

Relay Therapeutics

Sana Biotechnology

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Stoke Therapeutics

Tango Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Upstream Bio

Xencor

Zenas BioPharma

Zymeworks

TD Cowen

Cantor Fitzgerald

HC Wainwright & Co.

B of A Securities

Citigroup

Comments

Novavax

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO